Taniguchi Riki, Nambu Ryusuke, Ichimura Kayoko, Yoshida Masashi, Hara Tomoko, Iwama Itaru
Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama, 3308777, Japan.
Department of Pathology, Saitama Children's Medical Center, Saitama, Japan.
Clin J Gastroenterol. 2025 Apr;18(2):278-281. doi: 10.1007/s12328-025-02096-0. Epub 2025 Jan 20.
Eosinophilic gastrointestinal disorders (EGIDs) are treated with corticosteroids and food allergen elimination. However, treatment for refractory cases is not standardized. We demonstrate the efficacy of vedolizumab, an anti-α4β7 integrin agent, in 2 children with duodenal ulcers developed by non-eosinophilic esophagitis EGIDs. In both, vedolizumab was used continuously without side effects, and long-term remission has been durable. Duodenal ulcers associated with EGIDs are increasing. Vedolizumab has potential as a treatment for even upper gastrointestinal lesions in refractory EGIDs.
嗜酸性胃肠道疾病（EGIDs）采用皮质类固醇和消除食物过敏原进行治疗。然而，难治性病例的治疗尚无标准化方案。我们证明了抗α4β7整合素药物维多珠单抗对2例由非嗜酸性食管炎EGIDs引发十二指肠溃疡的儿童有效。在这两例患者中，持续使用维多珠单抗均无副作用，且长期缓解效果持久。与EGIDs相关的十二指肠溃疡病例正在增加。维多珠单抗在难治性EGIDs的上消化道病变治疗中具有潜在应用价值。
